➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Moodys
McKinsey
Harvard Business School
Merck

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Birinapant


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Birinapant?

Birinapant is an investigational drug.

There have been 12 clinical trials for Birinapant. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2012.

The most common disease conditions in clinical trials are Ovarian Neoplasms, Fallopian Tube Neoplasms, and Peritoneal Neoplasms. The leading clinical trial sponsors are TetraLogic Pharmaceuticals, National Cancer Institute (NCI), and Jonsson Comprehensive Cancer Center.

There are thirty-eight US patents protecting this investigational drug and four hundred and sixty-four international patents.

Recent Clinical Trials for Birinapant
TitleSponsorPhase
Birinapant and Intensity Modulated Re-Irradiation Therapy for Local-Regionally Recurrent Head and Neck Squamous Cell CarcinomaNational Cancer Institute (NCI)Phase 1
Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell CarcinomaNational Cancer Institute (NCI)Phase 1
Dose-escalation Study of Birinapant and Pembrolizumab in Solid TumorsMerck Sharp & Dohme Corp.Phase 1/Phase 2

See all Birinapant clinical trials

Clinical Trial Summary for Birinapant

Top disease conditions for Birinapant
Top clinical trial sponsors for Birinapant

See all Birinapant clinical trials

US Patents for Birinapant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Birinapant   Get Started Free SMAC Mimetic TetraLogic Birinapant UK Ltd. (Birmingham, GB)   Get Started Free
Birinapant   Get Started Free SYK inhibitors GILEAD SCIENCES, INC. (Foster City, CA)   Get Started Free
Birinapant   Get Started Free Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Get Started Free
Birinapant   Get Started Free Spiro[3H-indole-3,2'-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Birinapant

Drugname Country Document Number Estimated Expiration Related US Patent
Birinapant African Regional IP Organization (ARIPO) AP3619 2029-07-02   Get Started Free
Birinapant Argentina AR077629 2029-07-02   Get Started Free
Birinapant Australia AU2010266525 2029-07-02   Get Started Free
Birinapant Brazil BRPI1013958 2029-07-02   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Medtronic
AstraZeneca
Johnson and Johnson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.